US20230277581A1 - Polyglutamic acid compositions and methods of using - Google Patents
Polyglutamic acid compositions and methods of using Download PDFInfo
- Publication number
- US20230277581A1 US20230277581A1 US18/177,720 US202318177720A US2023277581A1 US 20230277581 A1 US20230277581 A1 US 20230277581A1 US 202318177720 A US202318177720 A US 202318177720A US 2023277581 A1 US2023277581 A1 US 2023277581A1
- Authority
- US
- United States
- Prior art keywords
- composition
- polyglutamic acid
- acid compound
- vaginal
- suppository
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 108010020346 Polyglutamic Acid Proteins 0.000 title claims abstract description 86
- 229920002643 polyglutamic acid Polymers 0.000 title claims abstract description 86
- 238000000034 method Methods 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 239000000829 suppository Substances 0.000 claims abstract description 20
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims abstract description 16
- 238000009472 formulation Methods 0.000 claims abstract description 13
- 208000024891 symptom Diseases 0.000 claims abstract description 13
- 230000009245 menopause Effects 0.000 claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 239000003906 humectant Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 239000002511 suppository base Substances 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010056530 Vulvovaginal pruritus Diseases 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 10
- 239000002253 acid Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 6
- -1 i.e. Chemical class 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011121 vaginal smear Methods 0.000 description 4
- 229940120293 vaginal suppository Drugs 0.000 description 4
- 239000006216 vaginal suppository Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- NGPTYCZGBCGWBE-UHFFFAOYSA-N decanoic acid hexadecanoic acid octadecanoic acid octanoic acid propane-1,2,3-triol Chemical group OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O NGPTYCZGBCGWBE-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010000849 leukocyte esterase Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
Definitions
- Vaginal dryness is a common condition that can affect women of all ages. However, vaginal dryness is most common in women following menopause. In postmenopausal women, vaginal dryness may be associated with declining estrogen levels. Topical estrogen therapy has been the most common treatment for vaginal dryness but this therapy carries risks such as vaginal bleeding and increased risk of uterine cancer. An alternative therapy for patients unwilling or unable to consider an estrogen therapy is hyaluronic acid. Yet, it also has adverse effect including vulvovaginal candidiasis and bacterial vaginosis. As such, the prior art methods and compositions for treatment of vaginal dryness are insufficient and solutions are provided herein to help alleviate vaginal dryness.
- Embodiments of the present disclosure relate to novel compositions containing one or more polyglutamic acid compounds and their use in the treatment and/or amelioration of the symptoms of vaginal dryness and the symptoms associated with menopause.
- compositions comprising one or more polyglutamic acid compounds and a pharmaceutically acceptable carrier.
- Each polyglutamic acid compound can be prepared by reacting a glutamic ester monomer with a suitable initiator.
- the molecular weight of each polyglutamic acid compound is determined by the number of the glutamic acid monomers that have been linked, corresponding to an n value set forth below.
- N refers to a chain length of a polyglutamic acid compound and can be between 300 and 30,000.
- the molecular weight of a polyglutamic acid compound of the disclosure can be between about 50 and 4,000 kDa.
- the composition described herein can contain one or more polyglutamic acid compounds that can have different polymer chain lengths (i.e., different n values).
- a composition can be comprised of a first polyglutamic acid compound, wherein the first polyglutamic acid compound has an n value of between about 300 and 500; a second polyglutamic acid compound, wherein the second polyglutamic acid compound has an n value between about 1,000 and 10,000; and a third polyglutamic acid compound, wherein the third polyglutamic acid compound has an n value between about 20,000 and 30,000.
- a composition can comprise one, two, three, four, five, six, or more different polyglutamic acid compounds that have different n values.
- compositions containing one or more polyglutamic acid compounds of the instant disclosure produce unexpectedly superior results due to the compounds’ ability to penetrate varying layers of vaginal epithelial tissue depending upon the particular ratio of polyglutamic acid compounds having different n values.
- a composition can comprise a first polyglutamic acid compound and a second polyglutamic acid compound, wherein the first polyglutamic acid compound has an n value that is less than the second polyglutamic acid compound. It is believed that a polyglutamic acid compound having a smaller n value is able to penetrate into deeper layers of the vaginal epithelium than a polyglutamic acid compound with a larger n value.
- a second polyglutamic acid compound having an n value greater than a first polyglutamic acid compound will not penetrate into deeper epithelial layers, but rather, the second polyglutamic acid compound will stay closer to the surface than the first polyglutamic acid compound.
- Certain embodiments comprise a first polyglutamic acid compound, a second polyglutamic acid compound, and a third polyglutamic acid compound.
- the first polyglutamic acid compound is a polyglutamic acid compound comprising a greater number of glutamic acid monomers than the second polyglutamic acid compound.
- the second polyglutamic acid compound comprises a greater number of glutamic acid monomers than the third polyglutamic acid compound.
- the first polyglutamic acid compound is configured to penetrate into the stratus corneum layer of a subject’s vaginal wall
- the second polyglutamic acid compound is configured to penetrate into the stratum granulosum layer of a subject’s vaginal wall
- the third polyglutamic acid compound is configured to penetrate into the stratum spinosum layer of a subject’s vaginal wall.
- one or more of the polyglutamic acid compounds can have an n value large enough such that it does not penetrate any skin layers, but stays on the skin surface, and can act as a lubricant.
- each polyglutamic acid compound in any of the compositions described herein is not particularly limited, and may be about 10 ⁇ g to about 10 g.
- the amount can be 10 ⁇ g, 15 ⁇ g, 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 35 ⁇ g, 40 ⁇ g, 45 ⁇ g, 50 ⁇ g, 55 ⁇ g, 60 ⁇ g, 65 ⁇ g, 70 ⁇ g, 75 ⁇ g, 80 ⁇ g, 85 ⁇ g, 90 ⁇ g, 95 ⁇ g, 100 ⁇ g, 125 ⁇ g, 150 ⁇ g, 175 ⁇ g, 200 ⁇ g, 225 ⁇ g, 250 ⁇ g, 275 ⁇ g, 300 ⁇ g, 325 ⁇ g, 350 ⁇ g, 375 ⁇ g, 400 ⁇ g, 425 ⁇ g, 450 ⁇ g, 475 ⁇ g, 500 ⁇ g, 525 ⁇ g, 575 ⁇ g, 600 ⁇ g, 625 ⁇ g, 650
- compositions disclosed herein can be used to treat, prevent, or alleviate vaginal dryness, vaginal itching, and/or vaginal burning.
- the compositions described herein can be used to maintain healthy levels of vaginal moisture.
- the compositions described herein can be used to accelerate the rate of wound healing, prevent urinary tract infections, and/or maintain pH values in a vaginal tissue.
- a composition as described herein is administered to a subject to avoid painful intercourse.
- a composition as described herein is administered to a subject to rejuvenate a vaginal tissue.
- a composition can be administered to a subject’s vaginal tissue to treat, prevent, ameliorate, and/or reduce the symptoms of vaginal dryness.
- a composition can be administered to a subject’s vaginal tissue to maintain a healthy level of vaginal moisture.
- a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate the symptoms of vaginal dryness due to menopause.
- a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate one or more symptoms of menopause.
- a composition can be administered to a subject’s vaginal tissue to reduce the pain associated with sexual activity, including sexual intercourse.
- a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate vaginal itching.
- a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate vaginal burning.
- a composition can be used for one or more of the foregoing.
- compositions disclosed herein are in the form of pharmaceutically effective salts.
- pharmaceutically acceptable salt(s), is art recognized and, as used herein includes, but is not limited to, salts of acidic or basic groups that may be present in the compositions disclosed herein.
- Compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glycerate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesul
- Compounds present in the compositions disclosed herein that include an amino moiety also can form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
- Compounds present in the compositions disclosed herein that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
- Non limiting examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium lithium, zinc, potassium, silicon, phosphorus, and iron salts.
- phrases “pharmaceutically acceptable carrier” is art-recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals.
- the carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, glycerides, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents
- esters refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent.
- Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst.
- Hydroxyls can be converted into esters via treatment with an esterifying agent such as alkanoyl halides.
- the term also includes lower hydrocarbon groups capable of being solvated under physiological conditions, e.g., alkyl esters, methyl, ethyl, and propyl esters.
- compositions described herein is not particularly limited.
- the composition is formulated as a topical, such as a cream or an ointment.
- the composition is formulated as a gel.
- the composition is formulated as a suppository.
- a suppository formulation comprises one or two polyglutamic acid compounds, a solubilizer, a humectant, a surfactant, and/or one or more suppository bases.
- An emollient can also be included in a suppository formulation.
- An example of a solubilizer is water.
- An example of a humectant is glycerin.
- An example of a surfactant is polysorbate 80.
- suppository bases are PEG4000, Gelucire 43/01, PEG3350, witepsol W-35 ® , and saturated fatty acids glycerides C 12 -C 18 .
- An example of an emollient is softisan 378.
- the one or two polyglutamic acid compounds have molecular weights ranging from 50 kDa to 2000 kDa.
- the molecular weight of a polyglutamic acid compound can be 50 kDa, 100 kDa, 150 kDa, 200 kDa, 250 kDa, 300 kDa, 350 kDa, 400 kDa, 450 kDa, 500 kDa, 550 kDa, 600 kDa, 650 kDa, 700 kDa, 750 kDa, 800 kDa, 850 kDa, 900 kDa, 950 kDa, 1000 kDa, 1050 kDa, 1100 kDa, 1150 kDa, 1200 kDa, 1250 kDa, 1300 kDa, 1350 kDa, 1400 kDa, 1450 kDa, 1500 kDa, 1550 kDa, 1600
- each polyglutamic acid compound in any of the compositions described herein is not particularly limited and can range from about 0.01% to about 1%.
- it can be 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.20%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.30%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.40%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.50%, 0.51%, 0.52%
- the weight percentages (% w/w) of the solubilizer, the humectant, the surfactant, the one or more suppository bases, and the emollient in the suppository formulation are also not particularly limited and can range, respectively, from 1% to 100%, from about 0.1% to 11.4%, from 0.1% to 1.4%, from 0% to 100%, and from 0% to 100%.
- the amount of the polyglutamic acid compounds, the solubilize, the humectant, the surfactant, the suppository bases and/or the emollient are in a synergistic ratio.
- a “synergistic ratio” refers to a ratio that elicits an unexpectedly superior pharmacological and physiological effect in a subject.
- An example of the synergistic ratio of the amount of the polyglutamic acid compound to the amount of the solubilizer to the amount of the humectant to the amount of the surfactant, and to the amount of the suppository base is 5:396:50:28:1521.
- a suppository formulation comprises only one polyglutamic acid compound.
- the compound has a molecular weight of 100 kDa, 700 kDa, or 2000 kDa.
- a suppository formulation contains a solubilizer, a humectant, a surfactant, and a suppository base.
- the solubilizer is water
- the humectant is glycerin
- the surfactant is polysorbate 80
- the suppository base is saturated fatty acids glycerides C 12 -C 18 .
- a suppository formulation comprises two polyglutamic acid compounds.
- the compounds have molecular weights of 100 kDa and 700 kDa.
- suppository formulations can be disintegrated between 5-10 minutes, between 10-20 minutes, or between 20-30 minutes.
- a suppository formulation can be administered every two days, every three days, every four days, every five days, every six days, every week, every eight days, every nine days, every ten days, every two weeks, every month, or more to provide fast and long-lasting relief of the symptoms of vaginal dryness and the symptoms associated with menopause.
- polyglutamic acid (mw: 100 kDa; 5 mg; 0.25% w/w) was mixed with water (396 mg; 19.8% w/w), glycerin (50 mg; 2.5% w/w), polysobrate 80 (28 mg; 1.4% w/w), and saturated fatty acids glycerides C 12 -C 18 (1521 mg; 76.04% w/w) to yield a white suppository.
- a dissolution study of the suppository was conducted by using a phosphate buffer that has a pH range of about 4.2-4.5, which is within a range of normal vaginal pH (3.8-5.0). Percentages of polyglutamic acid in the buffer at hour 0.5, hour 0.75, hour 1, hour 2, hour 3, hour 6, hour 24, hour 30, and hour 48 were determined. The dissolution data are shown in Table 1 below.
- the vaginal suppository composition described in example 1 above will be studied to evaluate its short-term stability as compared to a placebo prototype composition.
- the placebo composition will be identical to the vaginal suppository composition except that the former does not contain any polyglutamic acid compound. Both compositions will be placed on ICH stability at 2-8° C. and 25° C./60%RH conditions for 3 months. At the end of month 1 and month 2, the stability of the vaginal suppository composition will be evaluated by visual appearance and the amount of the polyglutamic acid compound remained in the composition.
- the stability of the vaginal suppository composition will be evaluated by, in addition to visual appearance and the amount of polyglutamic acid remaining in the composition, the amount of the polyglutamic acid compound dissolved.
- the placebo composition its stability will be evaluated by visual appearance and placebo interference at the end of each month.
- an assay will be conducted where an in vitro vaginal tissue test apparatus will be used to test the activity and efficacy of varying polymer lengths of polyglutamic acid compounds.
- the varying polyglutamic acid compounds i.e., with different n values
- their ability to penetrate into the various tissue layers of the vaginal wall will be correlated with their n value (i.e., the number of monomers in the polyglutamic acid compound), and the relative effect on vaginal moisture.
- compositions having varying concentrations of polyglutamic acid compounds with different polymer chain lengths i.e., different n values
- compositions described herein will be tested for their effects on the vaginal epithelium in a postmenopausal rat model.
- Rats that exhibited regular 4-days oestrous cycle will be chosen for the experiment.
- the rats will be divided into seven groups as shown in Table 2.
- rats will be ovariectomized (OVX) or given a sham operation (control) under anesthesia.
- the same weight of adipose tissue will be removed from rats in the control group.
- the vaginal smears will be assessed daily. Only rats whose vaginal smears that have exhibited regular 4-days cycles (before and after sham/OVX) and rats that exhibited constant leukocytes (after OVX) will be used (10 rats for each group).
- the rest of rats will be dosed intra-vaginally or orally with the same volume of placebo (vehicle) gel as rats that received a composition.
- the body weights of rats will be measured weekly.
- each composition for vaginal atrophy will be determined by a vaginal smear obtained from each rat, with a histological examination of a vaginal tissue. Vaginal smears will be fixed and detected, the expression of leukocyte esterase, ⁇ -glucuronidase, and coagulase will be used to determine the effect of each composition on vaginal microecosystem. Then all rats will be sacrificed by cervical dislocation and their vagina and uterus will be removed. The wet weight of each uterus will be determined once they will be carefully cleaned of any adherent tissue. To minimize variability due to dissection, all uteri will be dissected above the cervix at the same distance.
- vaginal tissue will be then removed and will be cut into 1 mm ⁇ 1 mm ⁇ 2 mm sections, stained with 2.5% glutaraldehyde. Some vaginal samples will be taken and processed for histological examination by standard procedures (4-5 ⁇ m sections stained with haematoxylin plus eosin).
- the repair capacity of each composition will be detected by Western blot.
- Vaginal VEGF, p-AKT, COX-2, ER ⁇ , and ER ⁇ will be detected by Western blot method.
- proteins will be separated in 10% polyacrylamide gel, electrotransferred topolyvinylidene fluoride membranes, and the bands will be blocked in 5% dried milk for 1 hour at room temperature and incubated with different primary antibodies (1:1000). The incubation will be carried out in PBS supplemented with 5% skim milk powder.
- TBS-T Tris-Buffered Saline
- TBS-T Tris-Buffered Saline
- antigen-antibody complex will be visualized by using an enhanced-chemiluminescence-detection kit.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 63/315,964 filed on Mar. 2, 2022, the disclosure of which is incorporated herein by reference in its entirety.
- Vaginal dryness is a common condition that can affect women of all ages. However, vaginal dryness is most common in women following menopause. In postmenopausal women, vaginal dryness may be associated with declining estrogen levels. Topical estrogen therapy has been the most common treatment for vaginal dryness but this therapy carries risks such as vaginal bleeding and increased risk of uterine cancer. An alternative therapy for patients unwilling or unable to consider an estrogen therapy is hyaluronic acid. Yet, it also has adverse effect including vulvovaginal candidiasis and bacterial vaginosis. As such, the prior art methods and compositions for treatment of vaginal dryness are insufficient and solutions are provided herein to help alleviate vaginal dryness.
- Embodiments of the present disclosure relate to novel compositions containing one or more polyglutamic acid compounds and their use in the treatment and/or amelioration of the symptoms of vaginal dryness and the symptoms associated with menopause.
- These and other features, aspects, and advantages of the present embodiments will become understood with reference to the following description and appended claims.
- Described herein are compositions comprising one or more polyglutamic acid compounds and a pharmaceutically acceptable carrier. Each polyglutamic acid compound can be prepared by reacting a glutamic ester monomer with a suitable initiator. The molecular weight of each polyglutamic acid compound is determined by the number of the glutamic acid monomers that have been linked, corresponding to an n value set forth below.
- The structure of a polyglutamic acid compound is depicted below:
- N refers to a chain length of a polyglutamic acid compound and can be between 300 and 30,000. The molecular weight of a polyglutamic acid compound of the disclosure can be between about 50 and 4,000 kDa. The composition described herein can contain one or more polyglutamic acid compounds that can have different polymer chain lengths (i.e., different n values).
- For example, and without limitation, a composition can be comprised of a first polyglutamic acid compound, wherein the first polyglutamic acid compound has an n value of between about 300 and 500; a second polyglutamic acid compound, wherein the second polyglutamic acid compound has an n value between about 1,000 and 10,000; and a third polyglutamic acid compound, wherein the third polyglutamic acid compound has an n value between about 20,000 and 30,000.
- The number of polyglutamic acid compounds having different n values in a composition is not particularly limited. In some embodiments, a composition can comprise one, two, three, four, five, six, or more different polyglutamic acid compounds that have different n values.
- Without being bound to any particular theory, the compositions containing one or more polyglutamic acid compounds of the instant disclosure produce unexpectedly superior results due to the compounds’ ability to penetrate varying layers of vaginal epithelial tissue depending upon the particular ratio of polyglutamic acid compounds having different n values. For example, a composition can comprise a first polyglutamic acid compound and a second polyglutamic acid compound, wherein the first polyglutamic acid compound has an n value that is less than the second polyglutamic acid compound. It is believed that a polyglutamic acid compound having a smaller n value is able to penetrate into deeper layers of the vaginal epithelium than a polyglutamic acid compound with a larger n value. And it is further believed that a second polyglutamic acid compound having an n value greater than a first polyglutamic acid compound will not penetrate into deeper epithelial layers, but rather, the second polyglutamic acid compound will stay closer to the surface than the first polyglutamic acid compound.
- Certain embodiments comprise a first polyglutamic acid compound, a second polyglutamic acid compound, and a third polyglutamic acid compound. In certain embodiments, the first polyglutamic acid compound is a polyglutamic acid compound comprising a greater number of glutamic acid monomers than the second polyglutamic acid compound. The second polyglutamic acid compound comprises a greater number of glutamic acid monomers than the third polyglutamic acid compound. In certain embodiments, the first polyglutamic acid compound is configured to penetrate into the stratus corneum layer of a subject’s vaginal wall, the second polyglutamic acid compound is configured to penetrate into the stratum granulosum layer of a subject’s vaginal wall, and the third polyglutamic acid compound is configured to penetrate into the stratum spinosum layer of a subject’s vaginal wall. In some embodiments, one or more of the polyglutamic acid compounds can have an n value large enough such that it does not penetrate any skin layers, but stays on the skin surface, and can act as a lubricant.
- The amount of each polyglutamic acid compound in any of the compositions described herein is not particularly limited, and may be about 10 µg to about 10 g. For example, the amount can be 10 µg, 15 µg, 20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, 55 µg, 60 µg, 65 µg, 70 µg, 75 µg, 80 µg, 85 µg, 90 µg, 95 µg, 100 µg, 125 µg, 150 µg, 175 µg, 200 µg, 225 µg, 250 µg, 275 µg, 300 µg, 325 µg, 350 µg, 375 µg, 400 µg, 425 µg, 450 µg, 475 µg, 500 µg, 525 µg, 575 µg, 600 µg, 625 µg, 650 µg, 675 µg, 700 µg, 725 µg, 750 µg, 775 µg, 800 µg, 825 µg, 850 µg, 875 µg, 900 µg, 925 µg, 950 µg, 975 µg, 1000 µg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, 1000 mg, 1.25 g, 1.5 g, 1.75 g, 2.0 g, 2.25 g, 2.5 g, 2.75 g, 3.0 g, 3.25 g, 3.5 g, 3.5 g, 3.75 g, 4.0 g, 4.25 g, 4.5 g, 4.75 g, 5.0 g, 5.25 g, 5.5 g, 5.75 g, 6.0 g, 6.25 g, 6.5 g, 6.75 g, 7.0 g, 7.25 g, 7.5 g, 7.75 g, 8.0 g, 8.25 g, 8.5 g, 8.75 g, 9.0 g, 8.25 g, 9.5 g, 9.75 g, 10 g, or any amount therebetween.
- The compositions disclosed herein can be used to treat, prevent, or alleviate vaginal dryness, vaginal itching, and/or vaginal burning. In some embodiments, the compositions described herein can be used to maintain healthy levels of vaginal moisture. In some embodiments, the compositions described herein can be used to accelerate the rate of wound healing, prevent urinary tract infections, and/or maintain pH values in a vaginal tissue. In certain embodiments, a composition as described herein is administered to a subject to avoid painful intercourse. In certain embodiments, a composition as described herein is administered to a subject to rejuvenate a vaginal tissue.
- In certain embodiments, a composition can be administered to a subject’s vaginal tissue to treat, prevent, ameliorate, and/or reduce the symptoms of vaginal dryness. In certain embodiments, a composition can be administered to a subject’s vaginal tissue to maintain a healthy level of vaginal moisture. In certain embodiments, a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate the symptoms of vaginal dryness due to menopause. In some embodiments, a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate one or more symptoms of menopause. In certain embodiments, a composition can be administered to a subject’s vaginal tissue to reduce the pain associated with sexual activity, including sexual intercourse. In certain embodiments, a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate vaginal itching. In certain embodiments, a composition can be administered to a subject’s vaginal tissue to treat, prevent, and/or ameliorate vaginal burning. In certain embodiments, a composition can be used for one or more of the foregoing.
- In some embodiments, the compositions disclosed herein are in the form of pharmaceutically effective salts. The phrase “pharmaceutically acceptable salt(s),” is art recognized and, as used herein includes, but is not limited to, salts of acidic or basic groups that may be present in the compositions disclosed herein. Compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glycerate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds present in the compositions disclosed herein that include an amino moiety also can form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds present in the compositions disclosed herein that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Non limiting examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium lithium, zinc, potassium, silicon, phosphorus, and iron salts.
- The phrase “pharmaceutically acceptable carrier” is art-recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals. The carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, glycerides, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. In one embodiment, the pharmaceutically acceptable carrier is suitable for intravenous administration. In another embodiment, the pharmaceutically acceptable carrier is suitable for locoregional injection.
- The term “pharmaceutically acceptable esters” refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. Hydroxyls can be converted into esters via treatment with an esterifying agent such as alkanoyl halides. The term also includes lower hydrocarbon groups capable of being solvated under physiological conditions, e.g., alkyl esters, methyl, ethyl, and propyl esters.
- The dosage form of compositions described herein is not particularly limited. In certain embodiments, the composition is formulated as a topical, such as a cream or an ointment. In certain embodiments, the composition is formulated as a gel. In certain embodiments the composition is formulated as a suppository.
- In certain embodiments, a suppository formulation comprises one or two polyglutamic acid compounds, a solubilizer, a humectant, a surfactant, and/or one or more suppository bases. An emollient can also be included in a suppository formulation. An example of a solubilizer is water. An example of a humectant is glycerin. An example of a surfactant is polysorbate 80. Examples of suppository bases are PEG4000, Gelucire 43/01, PEG3350, witepsol W-35®, and saturated fatty acids glycerides C12-C18. An example of an emollient is softisan 378. The one or two polyglutamic acid compounds have molecular weights ranging from 50 kDa to 2000 kDa. For examples, the molecular weight of a polyglutamic acid compound can be 50 kDa, 100 kDa, 150 kDa, 200 kDa, 250 kDa, 300 kDa, 350 kDa, 400 kDa, 450 kDa, 500 kDa, 550 kDa, 600 kDa, 650 kDa, 700 kDa, 750 kDa, 800 kDa, 850 kDa, 900 kDa, 950 kDa, 1000 kDa, 1050 kDa, 1100 kDa, 1150 kDa, 1200 kDa, 1250 kDa, 1300 kDa, 1350 kDa, 1400 kDa, 1450 kDa, 1500 kDa, 1550 kDa, 1600 kDa, 1650 kDa, 1700 kDa, 1750 kDa, 1800 kDa, 1850 kDa, 1900 kDa, 1950 kDa, or 2000 kDa. The weight percentage (% w/w) of each polyglutamic acid compound in any of the compositions described herein is not particularly limited and can range from about 0.01% to about 1%. For example, it can be 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.20%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.30%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.40%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.50%, 0.51%, 0.52%, 0.53%, 0.54%, 0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.60%, 0.61%, 0.62%, 0.63%, 0.64%, 0.65%, 0.66%, 0.67%, 0.68%, 0.69%, 0.70%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, 0.77%, 0.78%, 0.79%, 0.80%, 0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%, 0.90%, 0.91%, 0.92%, 0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1%, or more, or any value therebetween. The weight percentages (% w/w) of the solubilizer, the humectant, the surfactant, the one or more suppository bases, and the emollient in the suppository formulation are also not particularly limited and can range, respectively, from 1% to 100%, from about 0.1% to 11.4%, from 0.1% to 1.4%, from 0% to 100%, and from 0% to 100%. The amount of the polyglutamic acid compounds, the solubilize, the humectant, the surfactant, the suppository bases and/or the emollient are in a synergistic ratio. As used herein, a “synergistic ratio” refers to a ratio that elicits an unexpectedly superior pharmacological and physiological effect in a subject. An example of the synergistic ratio of the amount of the polyglutamic acid compound to the amount of the solubilizer to the amount of the humectant to the amount of the surfactant, and to the amount of the suppository base is 5:396:50:28:1521.
- In certain embodiments, a suppository formulation comprises only one polyglutamic acid compound. In certain embodiments, the compound has a molecular weight of 100 kDa, 700 kDa, or 2000 kDa. In certain embodiments, a suppository formulation contains a solubilizer, a humectant, a surfactant, and a suppository base. In certain embodiments, the solubilizer is water, the humectant is glycerin, the surfactant is polysorbate 80, and the suppository base is saturated fatty acids glycerides C12-C18.
- In certain embodiments, a suppository formulation comprises two polyglutamic acid compounds. In certain embodiments, the compounds have molecular weights of 100 kDa and 700 kDa.
- In certain embodiments, suppository formulations can be disintegrated between 5-10 minutes, between 10-20 minutes, or between 20-30 minutes. In certain embodiments, a suppository formulation can be administered every two days, every three days, every four days, every five days, every six days, every week, every eight days, every nine days, every ten days, every two weeks, every month, or more to provide fast and long-lasting relief of the symptoms of vaginal dryness and the symptoms associated with menopause.
- While the present invention has been described in some detail for purposes of clarity and understanding, one will appreciate that various changes in form and detail can be made without departing from the true scope of the invention.
- In one example, polyglutamic acid (mw: 100 kDa; 5 mg; 0.25% w/w) was mixed with water (396 mg; 19.8% w/w), glycerin (50 mg; 2.5% w/w), polysobrate 80 (28 mg; 1.4% w/w), and saturated fatty acids glycerides C12-C18 (1521 mg; 76.04% w/w) to yield a white suppository. A dissolution study of the suppository was conducted by using a phosphate buffer that has a pH range of about 4.2-4.5, which is within a range of normal vaginal pH (3.8-5.0). Percentages of polyglutamic acid in the buffer at hour 0.5, hour 0.75, hour 1, hour 2, hour 3, hour 6, hour 24, hour 30, and hour 48 were determined. The dissolution data are shown in Table 1 below.
-
TABLE 1 Dissolution Data Time (hr) % Dissolved Average (n=3) Std Dev %RSD 0.5 67.16 13.24 19.7 0.75 68.27 19.91 29.2 1 72.97 19.12 26.2 2 88.21 9.90 11.2 3 98.09 1.78 1.8 4 100.01 4.19 4.2 24 101.83 3.25 3.2 30 100.64 3.09 3.1 48 102.85 3.13 3.0 - It was observed that the suppository completely disintegrated within 30 minutes. The data shows that 67% of the polyglutamic acid compound was dissolved in 30 minutes and the polyglutamic acid compound was completely dissolved in the buffer at hour 3. Unexpectedly, a steady dissolution was observed from hour 0.5 to hour 3. Also unexpectedly, 100% of the polyglutamic acid compound remained in the buffer at hour 48, indicating that the compound is stable in a vaginal tissue and therefore, can moisturize the vaginal tissue for more than 2 days once administered. These unexpected results demonstrate that the composition can provide fast and long-lasting relief of the symptoms of vaginal dryness.
- The vaginal suppository composition described in example 1 above will be studied to evaluate its short-term stability as compared to a placebo prototype composition. The placebo composition will be identical to the vaginal suppository composition except that the former does not contain any polyglutamic acid compound. Both compositions will be placed on ICH stability at 2-8° C. and 25° C./60%RH conditions for 3 months. At the end of month 1 and month 2, the stability of the vaginal suppository composition will be evaluated by visual appearance and the amount of the polyglutamic acid compound remained in the composition. At the end of month 3, the stability of the vaginal suppository composition will be evaluated by, in addition to visual appearance and the amount of polyglutamic acid remaining in the composition, the amount of the polyglutamic acid compound dissolved. As to the placebo composition, its stability will be evaluated by visual appearance and placebo interference at the end of each month.
- An assay will be conducted where an in vitro vaginal tissue test apparatus will be used to test the activity and efficacy of varying polymer lengths of polyglutamic acid compounds. The varying polyglutamic acid compounds (i.e., with different n values) will be applied to the test apparatus, and their ability to penetrate into the various tissue layers of the vaginal wall will be correlated with their n value (i.e., the number of monomers in the polyglutamic acid compound), and the relative effect on vaginal moisture. In addition, compositions having varying concentrations of polyglutamic acid compounds with different polymer chain lengths (i.e., different n values) will be tested to ascertain the effect on vaginal moisture and penetration into vaginal tissue layers.
- Certain compositions described herein will be tested for their effects on the vaginal epithelium in a postmenopausal rat model.
- Thirty female Wistar/Sprague rats (eight-week-old) will be purchased from the Firat University Experimental Animal Center. All rats will be individually housed under clean conditions with controlled temperature, humidity, and light (12-h light-dark cycle) and provided a standard commercial diet and water ad libitum. All experimental procedures will follow the guidelines established by the Use of Laboratory Animals and will be approved by the Animal Care and Use Committee of Firat University.
- Rats that exhibited regular 4-days oestrous cycle will be chosen for the experiment. The rats will be divided into seven groups as shown in Table 2. After one adaptation period, rats will be ovariectomized (OVX) or given a sham operation (control) under anesthesia. The same weight of adipose tissue will be removed from rats in the control group. After the surgery, the vaginal smears will be assessed daily. Only rats whose vaginal smears that have exhibited regular 4-days cycles (before and after sham/OVX) and rats that exhibited constant leukocytes (after OVX) will be used (10 rats for each group). The rest of rats will be dosed intra-vaginally or orally with the same volume of placebo (vehicle) gel as rats that received a composition. The body weights of rats will be measured weekly.
-
TABLE 2 Study groups Groups Source HED Animal dose (per rat/day) (n=10 per arm)* 1 Saline - - 2 OVX - 3 OVX+ 5 mg 0.51 mg/kg BW 4 OVX+ 50 mg 5.14 mg/kg BW 5 OVX+ 500 mg 51.42 mg/kg BW 6 OVX+ 5000 mg 514.16 mg/kg BW 7 OVX+ 50 g 0.52 g/kg BW *Doses of products were converted by allometric scaling, which takes into account differences in body surface area to calculate equivalent doses for rat by the following calculation, assuming an 60 kg human: RD=HED(g)/60 kg*6.17 (For example: (50 mg /60)*6.17=5.14 mg/kg BW); where RD is the rat dosage of products, HED is the human equivalent dosage of products, and 6.17 is the conversion factor to convert a human dosage to a rat dosage - On day 15, the treatment effect of each composition for vaginal atrophy will be determined by a vaginal smear obtained from each rat, with a histological examination of a vaginal tissue. Vaginal smears will be fixed and detected, the expression of leukocyte esterase, β-glucuronidase, and coagulase will be used to determine the effect of each composition on vaginal microecosystem. Then all rats will be sacrificed by cervical dislocation and their vagina and uterus will be removed. The wet weight of each uterus will be determined once they will be carefully cleaned of any adherent tissue. To minimize variability due to dissection, all uteri will be dissected above the cervix at the same distance. The vaginal tissue will be then removed and will be cut into 1 mm × 1 mm × 2 mm sections, stained with 2.5% glutaraldehyde. Some vaginal samples will be taken and processed for histological examination by standard procedures (4-5 µm sections stained with haematoxylin plus eosin).
- The repair capacity of each composition will be detected by Western blot. Vaginal VEGF, p-AKT, COX-2, ERα, and ERβ will be detected by Western blot method. For Western blot, proteins will be separated in 10% polyacrylamide gel, electrotransferred topolyvinylidene fluoride membranes, and the bands will be blocked in 5% dried milk for 1 hour at room temperature and incubated with different primary antibodies (1:1000). The incubation will be carried out in PBS supplemented with 5% skim milk powder. After washing with Tris-Buffered Saline (TBS) containing 0.1% Tween-20 (TBS-T), the membranes will be further incubated with an anti-rabbit IgG antibody conjugated with horseradish peroxidase at room temperature for 1 hour. After washing with TBS-T, antigen-antibody complex will be visualized by using an enhanced-chemiluminescence-detection kit.
Claims (26)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/177,720 US20230277581A1 (en) | 2022-03-02 | 2023-03-02 | Polyglutamic acid compositions and methods of using |
US18/381,087 US20240050354A1 (en) | 2022-03-02 | 2023-10-17 | Polyglutamic acid compositions and methods of using |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263315964P | 2022-03-02 | 2022-03-02 | |
US18/177,720 US20230277581A1 (en) | 2022-03-02 | 2023-03-02 | Polyglutamic acid compositions and methods of using |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/381,087 Continuation-In-Part US20240050354A1 (en) | 2022-03-02 | 2023-10-17 | Polyglutamic acid compositions and methods of using |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230277581A1 true US20230277581A1 (en) | 2023-09-07 |
Family
ID=87851645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/177,720 Pending US20230277581A1 (en) | 2022-03-02 | 2023-03-02 | Polyglutamic acid compositions and methods of using |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230277581A1 (en) |
WO (1) | WO2023168365A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1644201A (en) * | 1998-04-17 | 2005-07-27 | 奥索-麦克尼尔药品公司 | Application of folic acid-containing pharmaceutical compositions |
CN103800219A (en) * | 2012-11-08 | 2014-05-21 | 山东福瑞达生物科技有限公司 | Multifunctional high-efficiency moisturizing stock solution |
-
2023
- 2023-03-02 WO PCT/US2023/063620 patent/WO2023168365A1/en unknown
- 2023-03-02 US US18/177,720 patent/US20230277581A1/en active Pending
Non-Patent Citations (4)
Title |
---|
Cooper et al., "Active agents, biomaterials, and technologies to improve biolubrication and strengthen soft tissues," Biomaterials 181 (2018) pp. 210-226 (Year: 2018) * |
Kumar et al., "Poly-gamma-glutamic acid: a promising biopolymer", Defense Life Science Journal, vol. 3, no. 3, 2018, July, pp. 301-306. (Year: 2018) * |
Ogunleye et al., "Poly-gamma-glutamic acid: production, properties and applications," Microbiology (2015), 161, 1-17 (Year: 2015) * |
Rosano et al., "Menopause and cardiovascular disease: the evidence," Climacteric, vol. 10, 2007-Issue sup 1 (abstract is only attached). (Year: 2007) * |
Also Published As
Publication number | Publication date |
---|---|
WO2023168365A1 (en) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10434059B2 (en) | Medicament for the treatment of viral skin and tumour diseases | |
US7781444B2 (en) | Pharmaceutical composition for treating fecal incontinence and anal itch | |
CZ20021014A3 (en) | Novel combination of loteprednol and antihistamines | |
US6207696B1 (en) | Compositions and methods for the prophylaxis and treatment of dysmenorrhea, endometriosis, and pre-term labor, using histidine | |
JPS61286382A (en) | Medical composition of endometritis in female mammal | |
JP2023184678A (en) | Compositions and methods for treating cutaneous fibrosis | |
US20230277581A1 (en) | Polyglutamic acid compositions and methods of using | |
US20240050354A1 (en) | Polyglutamic acid compositions and methods of using | |
ES2896680T3 (en) | Glucono delta lactone for the treatment of vaginal fungal infections | |
WO2020021509A2 (en) | Composition containing beclomethasone for the prevention and the treatment of bacterial prostatitis and vaginitis | |
US20200093858A1 (en) | Vaginal bioadhesive boric acid formulation and its preparation method | |
US20060204474A1 (en) | Treatment of epithelial layer lesions | |
Ojha et al. | An exhaustive statistic on current mucoadhesive intravaginal drug delivery methodologies | |
RU2747987C1 (en) | Composition for treatment of latent and subclinical papillomavirus infection of cervix and method for its application | |
EP3481370B1 (en) | Pharmaceutical composition comprising benzydamine | |
US20060100182A1 (en) | Pharmaceutical compositions for the treatment of urinary incontinence | |
PT1423126E (en) | Treatment of hyperproliferative conditions of body surfaces | |
KR20230039896A (en) | Vaginal cleaning composition | |
BR112020026708A2 (en) | COMPOSITIONS AND METHODS FOR TREATING TRICHOMONAS | |
WO2001082915A2 (en) | Trans-clitoral administration of therapy | |
Dogliotti et al. | 22 Hormonal Treatment | |
WO2004043471A1 (en) | Antipruritic drug | |
JPH0826993A (en) | Antipruritic agent | |
BR102013000829A2 (en) | PHARMACEUTICAL COMPOSITION FOR VAGINAL ADMINISTRATION AND USE OF PHARMACEUTICAL COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JDS THERAPEUTICS, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOMOROWSKI, JAMES R.;REEL/FRAME:062921/0726 Effective date: 20220304 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: BONAFIDE HEALTH, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JDS THERAPEUTICS, LLC;REEL/FRAME:065072/0787 Effective date: 20230926 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |